PowerPoint Presentation

WTF@OISUnconventional innovations challenging conventional wisdom

Gilbert H. Kliman, MDManaging DirectorInterWest Partners

Stephen Slade MD, FACSSurgeonSlade & Baker Vision, HoustonCo-Moderated By:

1

On your mobile device, open up the messaging APPBegin a new message and enter 22333 in the To: line and OISASCRS in the body hit sendYou are now ready to participate in the live polling!How do I participate?

2

Audience polling test question #1When you hear the letters WTF what is the first thing you think of?Whats The FutureWhiskey Tango Foxtrot movie with Tina FeySomething that is FUBAR

3

Major 20th Century Ophthalmic Innovations in Therapy

5

Major 20th Century Ophthalmic Innovations

Laser TherapyIntraocular LensPhacoemulsification

6

Sir Harold Ridley, 1940s Biocompatibility of intraocular foreign body Perspex in British fighter pilots could enable intraocular lenses

Gerd Meyer-Schwikerath, 1950s Retinal burns seen in observers of solar eclipses could be created therapeutically to treat retinal vascular disease

Charles Kelman, 1960sUltrasonic dental cleaning device could be re-purposed to emulsify the cataractous lens minimally invasively

7

7

WTF@OIS: WHATS THE FUTURE @OIS?

John Berdahl, MDFounder & CEO

Jim McCollumCo-Founder

Doug DanielsCEO

Curt LaBelleDirector

Robert BeckmanPresident & COO

8

On your mobile device, open up the messaging APPBegin a new message and enter 22333 in the To: line and OISASCRS in the body hit sendYou are now ready to participate in the live polling!How do I participate?

9

John Berdahl, MDFounder & CEO

10

11

The most compelling advantage of Balance Goggles is:

1. Complete Control of IOP (i.e setting the IOP for an individual patient)

2. Compliance

3. Synergistic with all existing therapies

12

Whats The Future for Equinox?

1. Bright: Major new treatment modality for glaucoma

2. Dim: This will never be a success

14

Jim McCollumCo-Founder

16

17

18

19

20

21

Would you use and pay out of pocket for a binocular drop that provides daily treatment for presbyopia?

1. Yes

2. No

22

Whats The Future for Liquid Vision?

1. Bright: Major new treatment modality for presbyopia

2. Dim: This will never be a success

24

Doug DanielsCEO

26

Confidential

ConfidentialStroma Medical is a clinical phase, ophthalmic, medical device company that is focused in eye aesthetics. We have designed, developed and patented a surgically non-invasive system that provides patients who wish to change their eye color from dark colors to blue with a safe effective procedure that takes approximately 30 seconds to perform.

A persons eyes are the first thing we see when we meet some one. It is how we connect with people. To help demonstrate my point, I would like to show you pictures of celebrities. The only thing different in the pictures is the color or the peoples eyes.

27

Mission and Vision: Leader in Eye AestheticsDesign, develop and patent a safe and natural eye color change

Projected Addressable Market:25M colored contact lens wearers worldwide/80% dark to light1.9M inquiries/16K volunteers for the trial17% of dark eyed individuals/43% of refractive patientsDark-eyed individuals ages 20-50 w/ relative affluence and desireRefractive surgeons/clinics & hospitalsCorporate Overview

Confidential

ConfidentialStromas mission is to be the leader in aesthetic enhancements for the eye. Our first product will be a laser based system to provide the options for people to change their eye color through a safe procedure that will create a natural looking eye color.

In order to achieve our goals and become a leader in the space the company has an experienced medical device senior management team. The Stroma senior team is comprised of leading laser scientists, optical and mechanical engineers and leading ophthalmic physicians. This team has over 130 years for experience in the space.

This is the fourth business that I have run. I had the good fortune including having run a division of Boston Scientific and during that time I helped to grow the division from $5M to $450M in global revenue. Gregg Homer, is the companies Founder, principle shareholder, and the CSO of the company. He currently has 3 PhDs and is truly a unique inventor and operator and he has a passion for this business.28

Addressable WW Market Opportunity

2.34M WW patients x $5,500 per patient= $10.5 B /year$2.9 B/yearPhysician Revenue:Company Revenue:

$1,250Click Fee

Confidential

Confidential29How do these numbers translate to real opportunity?

If we take the % of people who are darked eyed, affluent enough to afford, the % of individuals that are willing to do the procedure each year the Stroma opportunity represents a $9.36 B opportunity each year. From a company perspective the click fees represent a $2.9B opportunity.

The SystemProprietary and Confidential

Confidential

ConfidentialThe system is comprised of a combination of eye mapping, laser and eye tracking system linked together in a proprietary sosystem to safely and effectively change eye color. This is the system that is currently perfoming cases in Costa Rica. 30

Anatomy and Physiology of Eye Color Change

Confidential

ConfidentialA little on eye color and eye color change. All of us have blue eyes, or rather we have the potential for blue eyes. The color of your eyes is determined by the color of the pigment that resides in the anterior portion of the iris.

Even though the pigment is rather thin, if the pigment in the front of the iris is a dark color, hazel, brown or black than the light will be absorbed and your eyes will have a dark color. That pigment is only one cell layer thick so if it is removed and it allows the light to be reflected it give the eye a blue appearance. To help illustrate this, when the pigment is removed particially from an iris you can see how the eye presents as a blue eye.

31

Clinical Study Update 2Q 2016Proprietary and ConfidentialStage I & IICosta RicaClinica 20/20Dosimetry study/Full Iris20 patientsFollow for 2-3 months

StatusIn Stage I 70% CompletedNo ComplicationsIncreasing aesthetic resultsCompletion 6/16

Confidential

Confidential The company has now completed its initial animal and its 3 year follow-up on its first patients and is now in a formal Phase I process to gain OUS regulatory approvals. Right now Stroma is more than 60% through our Phase I clinical trial. In Phase I we are completing our dosimetry study on 20 patients. Our goal is to safely remove the pigment from the Stromal fibers and leaving the white stromal fibers behind. We are treating a total of 20 patients and studiying those patients for any signs of adverse reponses. So far we have not had a single adverse response and the energy is now sufficient to remove the pigment and achieve a positive response in less then a month.

.

32

Presentation Summary

Company has world class medical and business advisersSolid laser engineering and software talentDemonstrated safety in animal and human clinicalsHighly desire outcome market demand worldwideLarge markets with strong IP coverageGreat fit for the ophthalmic market infrastructurePositive economic incentives for rapid adoption

We hope you will join us to create options for patients and opportunities for the ophthalmic community!

Confidential

Confidential33In conclusion, Stroma has a world class team of industry professionals to carry out our plans, with solid engineering talent.We have demonstrated safety and now effectiveness in our recent clinical work. We have a big market, with good IP around both the procedure and the product features necessary to be safe and effective. We have a well understood quality, manufacturing and regulatory path the market. And for shareholders, Stroma is a great opportunity for a positive exit with a high ROI.

What percent of your dark eyed patients that have had refractive surgery would be interested in a proven safe and effective eye color changing procedure?

1. 10-20%

2. 20-30%

3. 30-40%

34

Whats The Future for Stroma?

1. Bright: Major new treatment for eye color change

2. Dim: This will never be a success

36

Curt LaBelleDirector

38

CONFIDENTIALOIS 2016

#

39

Eyenovias Solution

High-precision Micro-dosing of ophthalmic Rx 7 microliters vs. 50-70 microliters in eyedropsCharged to adhere to the corneaEliminates overflow and delivers directly to ocular surfaceSmart features to track dosing historyPiezoelectric technology to print therapeutics

Key Issues in Ophthalmology

100-year old legacy pipetting/dropper paradigmOverdosing of eye Rx delivers 10X more than eye can hold Overdosing of active drug and preservativeHard for patients to instill eye drops (elderly, arthritis)Excess dosing can lead to ocular and systemic side effects

EYENOVIA AT A GLANCETopical microdrops for high precision, smart delivery of eye pharmaceuticals

#

40

EYENOVIA: MICRO-DOSING AND SYSTEMIC TOXICITYMicrodose can improve therapeutic profile of many existing and new formulationsPlasma AUC 15-fold reduction Timolol 40 L vs 3 L4-fold more heart rate depression with standard Timolol dropsARVO 2014: http://iovs.arvojournals.org/article.aspx?articleid=22700533L microdose leads to 15 fold reduction in systemic AUC10-fold reduction in systemic AUC leads to 4-fold reduction in hear rate depressionPlasmaTimolol (40 L)Timolol (3 L)Cmax8.80.8Tmax0.50.5T1/20.70.4AUC0.5-8hours8.60.5Ratio AUC0.5-8hours 40 L versus 3 L15.6

Acta Ophthalmol Scand. 2005 Dec;83(6):723-8

#

41

StrategyImproved Ophthalmics in $19B MarketAdvantages:Higher therapeutic index- improved safety (topical and systemic)Enables FDA path for combination productsLower doseImproved safety profileLife cycle management for existing therapeuticsOptimized profile and technical success of new Rx (dry eye, glaucoma)

#

42

GlaucomaTimololPGA-Timo ComboPHN 400In-officePipeline: Launch 2-3 late stage programs in 2017Products: Target FDA approval of 2-3 branded ophthalmic products by 2019

3 YEAR HORIZONEYENOVIA PLAN

Y1Y2Y3

Phase II/IIIPhase II/IIIPhase II/III

#

43

EYENOVIA: Video Presentation

#

44

Which therapeutic areas should Eyenovia prioritize in the introduction of the high-precision, micro-Rx therapies (where is the beachfront?):

1. Glaucoma

2. Dry Eye

3. Allergy

45

Whats The Future for Eyenovia?

1. Bright: Major new drug delivery modality

2. Dim: This will never be a success

47

Robert BeckmanPresident & COO

49

BrainPort V100Electronic Vision AidRobert BeckmanCEO - Wicab, Inc.

50

How Do the Blind Perceive Their Surroundings?They form a mental image using their remaining senses:Touch a white cane provides a single point of contact Hearing echoes are amazingBrainPort V100 vision aid provides 400 points of contact and streaming patterns to refine that image.

51

How Does BrainPort V100 Work?Images from a glasses mounted video camera are processed and displayed on the tongue using an array of electrodesUsers learn to interpret stimulation as the scene around them

52

A Profoundly Blind User

53

BrainPort V100 BenefitsUsers enjoy increased mobility, independence, and confidenceEnhanced socialization with sighted peopleIncreased training and job opportunities

54

The Future of BrainPortHands free control and wireless connectivity to a smart phone or tabletPlatform of wireless computer vision apps similar to the driverless car

55

BrainPort Computer Vision for the BlindWicab is pursuing reimbursement in USA, France, & ChinaSells for less than 10% of a retinal implant and provides similar benefitsNot limited by etiology and useable by both acquired and congenitally blindNo surgical intervention required

56

Thank You!

www.Wicab.com

57

With over 250,000 profoundly blind people in the USA, should CMS/private insurance reimburse for this technology?

1. Yes

2. No

58

Whats The Future for BrainPort?

1. Bright: Major new visual aid for blindness

2. Dim: This will never be a success

60

62